AO World, Melrose, Oxford Biomedica: 3 FTSE stocks to buy

Follow us on Google News:
 AO World, Melrose, Oxford Biomedica: 3 FTSE stocks to buy
Image source: whiteMocca, Shutterstock

Highlights

  • The new cars registration in the UK dropped nearly 25% year-on-year in October 2021, as per the latest data released by the automotive industry body.
  • AO World Plc, Melrose Industries Plc, Oxford Biomedica Plc are some of the stocks in focus today.

The UK government’s commitment to achieve net zero carbon emissions by 2050 will require higher incentives that will push consumers to switch towards electric vehicles. Also, substantial investment needs to be made for charging infrastructure.

The electric cars demand has grown significantly in the country, which now accounts for 16% of total cars registered in the UK. The SMMT estimates a total of 287,000 new electric vehicles could be registered in 2021. Meanwhile, the new cars registration in the UK dropped nearly 25% year-on-year in October 2021, as per the latest data released by the automotive industry body The Society of Motor Manufacturers and Traders (SMMT). The industry body also said the shortage of semiconductor chips continues to hit the sector.

However, total new cars registration could be 1.66 million in the UK by the year-end, a rise of 1.9% compared to last year as per estimate. In addition,

Let us look at FTSE listed stocks that are in focus today:

AO World Plc (LON: AO.)

The company operates in the consumer discretionary sector, offering online electronic products in the UK and European markets. It also provides the finance on these products and delivers its products through an in-house logistics network. It reported a 5% growth in revenue, which was lower than previous periods in the six months ended 30 September 2021. The company said its growth was impacted due to the competitive online market, shortage of delivery drivers, and disruption in the global supply chain.

AO World Plc’s last close was at GBX 135 on 3 November 2021, with a market cap of £647.36 million.

Oxford Biomedica Plc (LON: OXB)

The company operates in the biotechnology segment engaged in developing fully integrated gene and cell therapy to treat serious diseases. It is one of the leading companies to manufacture Covid-19 vaccines commercially and includes big pharmaceutical companies like AstraZeneca, Novartis, Sanofi as its clients. The company has reported significant improvement in performance in the last few quarters. Its revenue rose by 139% at £81.3 million in the first six months of 2021, primarily due to growth in the commercial and bioprocessing segment.

Oxford Biomedica Plc’s last close was at GBX 1,550 on 3 November 2021, with a market cap of £1,334.38 million.

Melrose Industries Plc (LON: MRO)

The company operates as a diversified industrial group offering its services to the aerospace, automotive and other industrial businesses. FTSE100 listed company continues to witness robust growth led by the aerospace business, which reported 16% higher revenue in the three months ended 30 September 2021, mainly due to restructuring. However, the company’s automotive division witnessed slow growth because of supply constraints caused by the shortage of semiconductors in the industry.

Melrose Industries Plc’s last close was at GBX 158.60 on 3 November 2021, with a market cap of £6,934.67 million.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (Kalkine Media, we or us) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalised advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.